Welcome to our dedicated page for Roche Hldg news (Ticker: RHHBY), a resource for investors and traders seeking the latest updates and insights on Roche Hldg stock.
Roche Holding Ltd. (RHHBY) reports healthcare developments across medicines, diagnostics and digital health, including updates from Genentech as a member of the Roche Group. Recurring news covers operating and financial results, regional sales trends, product performance and regulatory disclosures tied to the company’s pharmaceutical and diagnostic portfolios.
Company updates frequently feature ophthalmology products and pipeline assets such as Vabysmo, Susvimo and vamikibart across retinal conditions including diabetic macular edema and neovascular age-related macular degeneration. Roche also reports clinical data in neurology and autoimmune disease, including fenebrutinib in multiple sclerosis and ENSPRYNG in myelin oligodendrocyte glycoprotein antibody-associated disease, along with diagnostics approvals and patient-education initiatives.
Roche (OTCQX: RHHBY) shareholders approved all Board proposals at the 10 March 2026 Annual General Meeting. Key outcomes: re-election of Severin Schwan as Chairman, 39th consecutive dividend increase to CHF 9.80 per share, approval to exchange Genussscheine for Participation Certificates (ticker ROP), and reduction of nominal share value to CHF 0.001.
Shareholders representing 77.22% of shares attended; key votes passed with high majorities, and KPMG AG was appointed statutory auditor for 2026.
Genentech (OTCQX: RHHBY) announced Phase III persevERA results in ER-positive, HER2-negative advanced breast cancer on March 9, 2026. The study did not meet its primary endpoint of a statistically significant progression-free survival benefit for giredestrant plus palbociclib versus letrozole plus palbociclib, though a numerical improvement was observed.
Adverse events were manageable and consistent with known safety profiles. Genentech cites positive evERA and lidERA readouts, FDA acceptance of an NDA based on evERA, and plans to submit lidERA data to the FDA in the coming weeks.
Roche (OTCQX: RHHBY) reported that the phase III persevERA study of giredestrant plus palbociclib in 1L ER+/HER2- advanced breast cancer did not meet its primary endpoint of a statistically significant improvement in progression-free survival, though a numerical improvement was observed.
Safety was manageable and consistent with known profiles. The FDA accepted a giredestrant NDA based on evERA data; lidERA phase III data will be submitted to the FDA in the coming weeks. Full persevERA results will be presented at a medical meeting; pionERA is expected to read out in 2027.
Roche (OTCQX: RHHBY) announced NEJM publication of phase III ALLEGORY data showing Gazyva/Gazyvaro (obinutuzumab) plus standard therapy significantly reduced SLE disease activity at 52 weeks. Primary SRI-4 response was 76.7% vs 53.5% (adjusted difference 23.1%, 95% CI 12.5–33.6; p<0.001).
All five key secondary endpoints were met, including BICLA, sustained glucocorticoid reduction to ≤7.5 mg/day, SRI-6, longer time to first BILAG flare (HR 0.58, p=0.002) and higher DORIS remission (35.1% vs 13.8%). Safety was consistent with the known profile.
Genentech (OTCQX: RHHBY) reported Phase III ALLEGORY results showing Gazyva plus standard therapy met the primary endpoint in systemic lupus erythematosus (SLE).
At 52 weeks, 76.7% of Gazyva patients achieved SRI-4 versus 53.5% with placebo (adjusted difference 23.1%, 95% CI: 12.5–33.6; p<0.001). All five key secondary endpoints were met and safety aligned with the known profile.
Genentech (OTCQX:RHHBY) reported positive Phase II topline results for petrelintide, an once-weekly amylin analog for chronic weight management. The ZUPREME-1 trial (n=493, mean BMI 37 kg/m2) showed up to 10.7% mean weight reduction at week 42 versus 1.7% placebo (p<0.001) and placebo-like tolerability.
No vomiting occurred at the maximally effective dose; treatment discontinuations due to adverse events were 4.8% with petrelintide versus 4.9% with placebo. Full data will be presented at a medical congress; ZUPREME-2 topline is expected in H2 2026.
Roche (OTCQX: RHHBY) reported positive Phase II ZUPREME-1 topline results for petrelintide, an investigational once-weekly amylin analog for chronic weight management. In 493 participants (mean BMI 37 kg/m2), petrelintide produced up to 10.7% mean body weight loss at week 42 versus 1.7% with placebo (p<0.001) and showed placebo-like tolerability.
The maximally effective dose had no vomiting and no discontinuations for GI adverse events; 98% reached maintenance dose. Roche plans further development, ZUPREME-2 topline in H2 2026, and a combination trial in 2026.
Roche (SIX: ROG) released a global survey of 4,326 people with diabetes across 22 countries on March 5, 2026, showing large day-to-day impacts from unpredictable glucose and a strong demand for predictive tools.
Key metrics: 80% would value predictive glucose tools; 61% report diabetes as a mental burden; 71% often feel tired. Roche will present related real-world evidence at ATTD on March 11, 2026.
Genentech (OTCQX: RHHBY) reported that Phase III FENhance 1 met its primary endpoint, showing fenebrutinib reduced annualized relapse rate by 51% versus teriflunomide over ≥96 weeks, consistent with FENhance 2 (-59%).
All three pivotal studies (including FENtrepid in PPMS) will be submitted to regulators and presented at AAN 2026. Safety notes: liver transaminase elevations were comparable; one Hy's Law case occurred in each arm; 8 fatal cases occurred in fenebrutinib arms versus 1 in teriflunomide, under further analysis.
Roche (OTCQX: RHHBY) reported that the pivotal Phase III study FENhance 1 met its primary endpoint, with investigational fenebrutinib reducing annualised relapse rate (ARR) by 51% versus teriflunomide over at least 96 weeks. This result aligns with FENhance 2 (59% ARR reduction).
Secondary endpoints showed significant reductions in brain lesions and favorable progression trends. Company plans to present full data at AAN 2026 and submit combined Phase III results, including FENtrepid in PPMS, to regulators. Safety signals include liver transaminase elevations comparable to teriflunomide and eight fatal cases in fenebrutinib arms under further analysis.